X4 Pharmaceuticals (XFOR) Free Cash Flow Growth (3y) (2020 - 2025)
X4 Pharmaceuticals (XFOR) Free Cash Flow Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 6.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.73% |
| Sep 30, 2025 | -12.91% |
| Jun 30, 2025 | -17.37% |
| Mar 31, 2025 | 15.16% |
| Dec 31, 2024 | -20.11% |
| Sep 30, 2024 | -32.07% |
| Jun 30, 2024 | -50.72% |
| Mar 31, 2024 | -21.12% |
| Dec 31, 2023 | -18.17% |
| Sep 30, 2023 | -63.24% |
| Jun 30, 2023 | -61.04% |
| Mar 31, 2023 | -18.15% |
| Dec 31, 2022 | -27.06% |
| Sep 30, 2022 | -14.54% |
| Jun 30, 2022 | -8.98% |
| Mar 31, 2022 | -19.90% |
| Dec 31, 2021 | -41.47% |
| Sep 30, 2021 | -30.31% |
| Jun 30, 2021 | -47.88% |
| Mar 31, 2021 | -45.24% |